Discovery Partners International News

Drug maker Infinity Pharmaceuticals Inc. has promoted President Adelene Q. Perkins to the role of CEO, effective Jan.

Infinity Pharmaceuticals, Inc. today announced that Adelene Q. Perkins will become the company's President and Chief Executive Officer, and join the company's Board of Directors, effective January 1, 2010 in accordance with an existing management succession plan.

Infinity Pharmaceuticals, Inc. , an innovative cancer drug discovery and development company, today announced that Adelene Q. Perkins, president and chief business officer, was named the 2009 "Best Executive: Non-Services Business" in the 6th Annual Stevie Awards for Women in Business, presented at the Annual Award Dinner and Ceremony held on ...

Infinity Pharmaceuticals Inc. said Monday its third-quarter loss narrowed on a boost in payments from its partnership with Purdue Pharmaceutical Products LP and Mundipharma International Corp.

Protein-focused biotech company Aileron Therapeutics Inc. has named Steven Kafka as its chief financial officer and vice president of finance and operations.

Infinity Pharmaceuticals, Inc. , an innovative cancer drug discovery and development company, announced today that Thomas J. Lynch, Jr., M.D., has been appointed to its Board of Directors.

Infinity Pharmaceuticals Inc. of Cambridge appointed Dr. Thomas Lynch a director and to the research and development committee of the board.

Infinity Pharmaceuticals Inc. , a cancer drug discovery and development company in Cambridge, has named Thomas Lynch, director of the Yale Cancer Center and physician-in-chief at Smilow Cancer Hospital, to its board of directors.

Infinity Pharmaceuticals, Inc. , an innovative cancer drug discovery and development company, today announced that management will present a company overview at several upcoming conferences.

News And FDA Updates For Theravance , Auxilium , Infinity Pharma , Momenta BioMedReports.com , the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA ...

Infinity Pharmaceuticals, Inc. , an innovative cancer drug discovery and development company, today announced that the chemistry and data leading to the discovery of its novel Hedgehog signaling pathway inhibitor, IPI-926, have been published in the Journal of Medicinal Chemistry.

Infinity Pharmaceuticals, Inc. , an innovative cancer drug discovery and development company, today announced that it was added to the Russell 2000 Index when Russell Investments reconstituted its comprehensive set of U.S. and global equity indexes on June 26, 2009.

Infinity Pharmaceuticals, Inc. - Financial and Strategic Analysis Review - New Company and Market Analysis 2009-06-12 21:15:02 - Infinity Pharmaceuticals, Inc.

Infinity Pharmaceuticals, Inc. is an innovative drug discovery company focused on discovering and developing novel small molecules as cancer therapeutics.

Infinity Pharmaceuticals, Inc. today presented promising data from two clinical trials of IPI-504, the company's heat shock protein 90 chaperone inhibitor.

Four top executives from Boston-area technology organizations were honored this week as recipients of the Second Annual Leadership Awards, presented by Women Entrepreneurs in Science and Technology .

Infinity Pharmaceuticals, Inc. , an innovative cancer drug discovery and development company, today announced that it has been named one of the "Best Places to Work" by both The Scientist and the Boston Business Journal.